Quarterly report [Sections 13 or 15(d)]

Subsequent Events (Details Narrative)

v3.26.3
Subsequent Events (Details Narrative) - $ / shares
Nov. 15, 2026
Sep. 30, 2026
Dec. 31, 2025
Subsequent Event [Line Items]      
Common stockshares issued   8,499,379 7,690,403
Subsequent Event [Member] | Pharma Cyte Biotech Inc [Member] | Consent and Waiver Agreement [Member]      
Subsequent Event [Line Items]      
Common stockshares issued 4,982,272    
Subsequent Event [Member] | Pharma Cyte Biotech Inc [Member] | Consent and Waiver Agreement [Member] | Series G Long-Term Warrants [Member]      
Subsequent Event [Line Items]      
Number of warrants exchanged 851,304    
Warrants exchanged Price Per Share $ 0.3101    
Subsequent Event [Member] | Pharma Cyte Biotech Inc [Member] | Consent and Waiver Agreement [Member] | Series H Preferred Stock [Member]      
Subsequent Event [Line Items]      
Exchange agreement maturity date Mar. 02, 2027    
Exchange agreement extension maturity date Sep. 02, 2027    
Subsequent Event [Member] | Pharma Cyte Biotech Inc [Member] | Consent and Waiver Agreement [Member] | Series G Preferred Stock and Series H Preferred Stock [Member]      
Subsequent Event [Line Items]      
Warrants exchanged Price Per Share $ 0.3101